Tag: exa-cel
-
Why CRISPR is Becoming a Standout Winner
CRISPR Therapeutics could be a standout winner this year, we said on April 13. We also noted, “Cantor Fitzgerald initiated coverage with an outperform rating, with a $72 price target, with the firm expecting CRSP to get a nod for its gene-editing therapy, exa-cel.” At the time, CRSP traded around $44. Today, it’s up to…